Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage
IIIB, stage IV, or recurrent non-small cell lung cancer. Bortezomib may interfere with the
growth of tumor cells by blocking certain enzymes necessary for tumor cell growth